Daiichi Sankyo, Inc., Eli Lilly and Company Say Heart Drug Effient Fails to Meet Goal in a Phase III Trial

Published: Aug 27, 2012

Daiichi Sankyo Co., Ltd. (DSKYF, DSNKY) and Eli Lilly and Co. (LLY:Quote) Sunday announced that their new heart drug Effient (prasugrel) failed to beat the older product Plavix (clopidogrel). The study named TRILOGY ACS did not meet primary objective of demonstrating prasugrel superiority over clopidogrel. Daiichi Sankyo and Eli Lilly co-developed Effient, an oral antiplatelet agent discovered by Daiichi Sankyo and its Japanese research partner, Ube Industries, Ltd. "While this is not the outcome we anticipated, we believe this study contributes to the knowledge base about ACS patients who are medically managed," said Glenn Gormley, Global Head of Research & Development and Senior Executive Officer, Daiichi Sankyo.

Back to news